A 51-year-old man was referred to gastroenterology for screening colonoscopy.
Family history includes pancreatic cancer on his father’s side and pre-menopausal breast cancer in his aunt.
Colonoscopy revealed a 3-cm mass, proximal to the hepatic flexure.
Biopsy confirmed the lesion to be of adenocarcinoma histology.
At the time, the patient underwent right hemicolectomy revealing a moderately differentiated tumor. Fifteen lymph nodes were removed and tested negative for metastatic disease, denoting stage T3N0M0 colon cancer.
The patient healed without complications and received no further treatment.
April 2015
The patient continued to feel well, except for occasional fatigue and diarrhea.
PET/CT scan revealed several small lesions in multiple lobes of the liver that were PET avid
Biopsy was performed and confirmed the liver lesions to be metastases from colon cancer
The patient was referred to a local oncologist and started on infusional 5-FU and oxaliplatin (FOLFOX) in combination with bevacizumab.
CT scan 2 months after starting treatment showed a partial response to therapy; at 4 months the patients tumor continued to shrink
Oxaliplatin was discontinued; subsequently the patient received maintenance therapy with capecitabine and bevacizumab, resulting in continued disease control
February 27, 2017
The patient has had stable disease for 22 months and remains on bevacizumab maintenance therapy.
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.